Compositions and methods for the treatment and diagnosis of immune disorders
Patent 6414117 Issued on July 2, 2002. Estimated Expiration Date: May 12, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/185.1, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same424/192.1, Fusion protein or fusion polypeptide (i.e., expression product of gene fusion)435/41, MICRO-ORGANISM, TISSUE CELL CULTURE OR ENZYME USING PROCESS TO SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/69.3, Antigens435/69.7, Fusion proteins or polypeptides435/70.1, Using tissue cell culture to make a protein or polypeptide435/71.1, Using a micro-organism to make a protein or polypeptide530/300, PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES536/22.1, N-glycosides, polymers thereof, metal derivatives (e.g., nucleic acids, oligonucleotides, etc.)536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/23.4Encodes a fusion protein
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.
Other References
Seder and Gros, 1995, "The functional role of CD*+ T helper type 2 cells", J Exp Med 181:5-7
Bergers et al., 1994, "Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor", EMBO J 13(5):1176-1188
Gavett et al., 1994, "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia", Am J Respir Cell Mol Biol 10:587-593
Kaneshima et al., 1994, "Human hematolymphoid cells in SCID mice", Curr Opin Immunol 6:327-333
Lukacs et al., 1994, "Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma", Am J Respir Cell Mol Biol 10:526-532
Maggi et al., 1994, "Th2-like CD8+ cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection", J Exp Med 180:489-495
Maggi et al., 1994, "Ability of HIV to promote a TH 1 to TH 0 shift and to replicate preferentially in TT 2 to TH 0 cells", Science 265:244-248
Manetti et al., 1994, "CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+ CD30+ cell clones in human immunodeficiency virus infection", J Exp Med 180:2407-2411
Marsh et al., 1994 "Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations", Science 264:1152-1156
Chen et al., 1993, "RAG-2-deficient blastocyst complementation: An assay of gene function in lymphocyte development" Proc Natl Acad Sci USA 90:4528-4532
Clerici et al., 1993, "Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro", Science 262:1721-1724
Clerici et al., 1993, "Changes in interleukin-2 and interleukin-4 production in asymptomatic-human immunodeficiency virus-seropositive individuals", J Clin Invest 91:759-765
Kanagawa et al., 1993, "Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS)", Science 262:240-242
Robinson et al., 1993, "Activation of CD4+ T cells, increased TT2 -type cytokine mRNA expression, eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma", J Allergy Clin Immunol 92:313-324
Yanagisawa et al., 1993, "Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1", FEBS Lett 318(1):83-87
Liang and Pardee, 1992, "Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction", Science 257:967-971
Shinkai et al., 1992, "RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement", Cell 68:855-867
Tominaga et al., 1992, "Nucleotide sequence of a complementary DNA for human ST2", Biochim Biophys Acta 1171:215-218
Werenskiold, 1992, "Characterization of a secreted glycoprotein of the immunoglobulin superfamily inducible by mitogen and oncogene", Eur J Biochem 204:1041-1047
Young et al., 1992, "Expression of cytolytic mediators by synovial fluid lymphocytes in rheumatoid arthritis", Am J Path 140(5):1261-1268
Del Prete et al., 1991, "Purified protein derivative of mycobacterium tuberculosis and excretory-secreted antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (Type 1 T helper or Type 2 T helper) profile f cytokine production", J Clin Invest 88:346-350
Ebnet et al., 1991, "In vivo primed mouse T cells selectively express T cell-specific serine proteinase-1 and the proteinase-like molecules granzyme B and C", Int Immunol 3(1):9-19
McMahan et al., 1991, "A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types", EMBO J 10(10):2821-2832
Moll et al., 1991, "Expression of T-cell-associated serine proteinase 1 during murine Leishmania major infection correlates with susceptibility to disease", Infect Immun 59(12):4701-4705
Mosmann and Moore, 1991, "The role of IL-10 in crossregulation TH 1 and TH 2 responses", Immunol Today 12:A49-A53
Tominaga et al., 1991, "Molecular cloning of the murine ST2 gene, Characterization and chromosomal mapping", Biochim Biophys Acta 1090:1-8
Yamamura et al., 1991, "Defining protective responses to pathogens: Cytokine profiles in leprosy lesions", Science 254:277-279
Makino et al., 1990, "H-2-associated and background genes influence the development of a murine retrovirus-induced immunodeficiency syndrome", J Immunol 144(11):4347-4355
Murphy et al., 1990, "Induction by antigen of intrathymic apoptosis od CD430 CD830 TCRlo thymocytes in vivo", Science 250:1720-1723
Ojcius and Young, 1990, "Cell-mediated killing: Effector mechanisms and mediators", Cancer Cells 2:138-145
Wiernenga et al., 1990, "Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients", J Immunol 144(12):4651-4656
Cooper et al., 1989, "Analysis of naturally occuring delayed-type hypersensitivity reactions in leprosy by in situ hybridization", J Exp Med 169:1565-1581
Firestein et al., 1989, "A new murine CD4+ T cell subset with an unrestricted cytokine profile", J Immunol 143(2):518-525
Klemenz et al., 1989, "Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen", Proc Natl Acad Sci USA 86:5708-5712
Liu et al., 1989, "Perforin and serine esterase gene expression in stimulated human T cells", J Exp Med 170:2105-2118
Mosmann and Coffman, 1989, "TH1 and TH2 cells: Differenct patterns of lymphokine secretion lead to different functional properties", Ann Rev Immunol 7:145-173
Tominaga, 1989, "A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor", FEBS Lett 258(2):301-304
Werenskiold et al., 1989, "Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts", Mol Cell Biol 9(11):5207-5214
Fruth et al., 1988, "Determination of frequency of T cells expressing the T cell-specific serine proteinase 1 (TSP-1) reveals two types of L3T4+ T lymphocytes", Eur J Immunol 18:773-781
Mueller et al., 1988, "A high proportion of T lymphocytes that infiltrate H-2-incompatible heart allografts in vivo express genes encoding cytotoxic cell-specific serine proteases, but do not express the MEL-14-defined lymph node homing receptor", J Exp Med 167:1124-1136
Gershenfeld and Weissman, 1986, "Clonin of a cDNA for a T cell-specific serine protease from a cytotoxic T lymphocyte", Science 232:854-858
Masson et al., 1986, "Identification of granzyme A isolated from cytotoxic T-lymphocytes-granules as one of the proteases encoded by CTL-specific genes", FEBS Lett 208(1):84-88
Masson et al., 1986, "Granules of cytotoxic T-lymphocytes contain two serine esterases", EMBO J 5(7):1595-1600
Gu et al., 1994, "Deletion of a DNA polymerase ଲ gene segment in T cells using cell-type specific gene targeting",Science 265:103-106
Larhammar et al., 1992, "Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type", J Biol Chem 267:10935-10938
Law et al., 1991, "Identification of the subunits of GTP-binding proteins coupled to somatostatin receptors", J Biol Chem 266:17885-17897
Gershenfeld et al., 1988, "Cloning and chromosomal assignment of a human cDNA encoding a T-cell-and natural killer cell-specific trypsin-like serine protease", Proc Natl Acad Sci USA 85:1184-1188
Ishidoh et al., 1987, "Molecular cloning and sequencing of cDNA for rat cathepsin H", FEBS Lett 226:33-37
Askew et al., 1989, "Molecular recognition with convergent functional groups. 6. Synthetic and structural studies with a mode receptor for nucleic acid components", J Am Chem Soc 111:1082-1090
Lewis et al., 1989, "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation", Proc R Soc Lond 236:125-140
Lewis et al., 1989, "Automated site-directed drug design: the formation of molecular templates in primary structure generation", Proc R Soc Lond 236:141-162
McKinlay et al., 1989, "Rational design of antiviral agents", Annu Rev Pharmacol Toxicol 29:111-22
Perry et al., QSAR: Quantitative structure-activity relationships in drug design, pp. 189-193 (Alan R. Liss, Inc. 1989)
Ripka, Jun. 16, 1988, "Computers picture the perfect drug", New Scientist pp. 54-58
Rouvinen et al., 1988, "Computer-aided drug design", Acta Pharmaceutica Fennica 97:159-166
Liew, F., 1994, "Induction and Regulation of CD4+ T Cell Subsets", CIBA Foundation Symposium 87:170-178
Volmer et al., 1994, "T Lymphocytes Derived From Skin Lesions of Patients with Psoriasis Vulgaris Express a Novel Cytokine Pattern that is Distinct from that of T Helper Type 2 Cells", Eur. J. Immunol. 24:2377-2382
Houge, G., 1993, "Simplified Construction of a Subtracted cDNA Library Using Asymmetric PCR", PCR Methods and Applications 2(3):204-209
Miller, A., 1992, "Human Gene Therapy Comes of Age", Nature 357:455-460
Tepper, R. et al., 1990, "IL-4 Induces Allergic-Like Inflammatory Disease and Alters T Cell Development in Transgenic Mice", Cell 62:457-467
Aruffo, A. et al., 1990, "CD44 Is the Principal Cell Surface Receptor for Hyaluronate", Cell 61:1303-1313
Chien, C. et al., 1991, "The Two-Hybrid System: A Method to Identify and Clone Genes for Proteins that Interact with a Protein of Interest", Proc. Natl. Acad. Sci. USA 88:9578-958
May 12, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
